Most material SEC filings — September 21, 2026

As of September 20, 2026, Bitmine held 5,983,940 ETH tokens (valued at $2,688/token = ~$16.1B), representing 4.9% of total ETH supply (122.1M ETH). Total holdings including 212 BTC, $180M Beast Industries stake, $105M Eightco stake, and $714M cash/marketable securities = $17.1B. Company has staked 5,067,309 ETH generating 2.62% annualized yield ($357M current, projected $421M at full scale). Bitmine added to Russell 1000 on June 26, 2026; Series A Preferred Stock (BMNP) trades on NYSE.

GT Biopharma closed a securities purchase on September 18, 2026, issuing 8,611.1111 shares of Series M 10% Convertible Preferred Stock (with stated value of $8.61M) for $7.75M cash to Five Narrow Lane, L.P., Bristol Investment Fund, Ltd., and newly added investor Nicholas R. Nikolov. The amendment also grants purchasers Greenshoe rights to purchase up to $34.68M additional stated value of preferred stock for $31.21M. Series M share count increased from 41,778 to 43,287 authorized shares.

Viking Acquisition Sponsor II, LLC advanced an additional $30,000 to Viking Acquisition Corp. II on September 18, 2026, increasing total principal owed from $514,080 to $544,080 under a restated promissory note. The debt is due upon initial business combination or wind-up, bears no interest, and is convertible at sponsor's option into post-combination units at $10.00 per unit. Sponsor waives all claims against the IPO trust account.

On September 21, 2026, Knightscope filed a prospectus supplement to its Form S-3 registration statement (effective April 11, 2025) covering an at-the-market (ATM) offering of up to $35M in Class A common stock. The offering is conducted under a Sales Agreement with H.C. Wainwright & Co., LLC, originally executed February 1, 2023. This is a legal opinion letter confirming the shares will be validly issued and fully paid.

On September 16, 2026, Bloomia Holdings (via subsidiary TULP 24.1, LLC) executed a Third Amendment to its credit agreement with Associated Bank, N.A., waiving existing Events of Default related to Fixed Charge Coverage Ratio and Senior Cash Flow Leverage Ratio breaches in Q4 2025 and Q1–Q2 2026. The amendment temporarily increases the revolving commitment from $6M to $10M through May 31, 2027, relaxes leverage and coverage covenants through Q2 2027, but introduces a $100K/month refinance fee (potentially $400K–$600K total) if neither a debt refinance nor $4M+ alternative capital raise closes by May 31, 2027. Three individuals (Philp, Jundt, Jansen) provided personal limited guaranties.

New ERA's subsidiary TCDC PowerCo LLC signed a 20-year PPA with Luminant ET Services (Vistra affiliate) for 200–207 MW of natural gas power to Phase 1 of its Texas Critical Data Center, with delivery expected Q3 2027. Concurrently, Vistra received a 5% non-voting interest in the powered portion post-commencement, plus right of first refusal on future TCDC expansion and right of first offer on other New ERA projects.

Inflection Point Acquisition Corp. VII (assets ~$234.4M) is combining with Elroy Air, Inc., a developer of autonomous hybrid-electric VTOL cargo aircraft (Chaparral). Elroy Air is valued at $800M pre-money in the transaction. The company has a pipeline of 1,410 aircraft units from customers including Bristow, FedEx, and Japanese Army; signed a $46M U.S. Army contract; and completed first eIPP autonomous flights in 2026. Elroy Air projects 4–6 aircraft unit sales and $25–35M total revenue in 2027, with cumulative operating and total cash burn of $27–32M and $32–39M respectively in 2026.

Evolution Metals Technologies Corp. (EMAT, $7.1M market cap) was added to the Russell 2000 and Russell 3000 indexes effective September 21, 2026, following FTSE Russell's third-quarter IPO additions process. The $12.2 trillion in benchmarked assets tied to these indexes will now mechanically include EMAT in index-tracking funds and institutional portfolios. The company simultaneously announced FY2027 revenue guidance of $400–$460 million and disclosed plans to expand Pohang production capacity to 10,000 metric tons annually with 13 additional ULVAC machines arriving November 2026.

Trio Petroleum (market cap ~$8.8M) entered a farmout agreement dated September 17, 2026 with Croverro Energy to participate in a multi-year development program across Alberta and Saskatchewan. Trio pays Croverro an initial prospect fee of CAD $450,000 and funds 100% of ~CAD $1.8M per 2-well earning program, earning 80% working interest until payout, then 60% thereafter. The program comprises up to 7 earning programs with 2 wells each (14 total multilateral wells), plus a re-entry and property acquisition. Croverro remains operator. Trio can elect not to participate in subsequent programs, with pro-rata refund of CAD $64,000 per skipped program.

Dick's Sporting Goods (market cap ~$11.3B) completed acquisition of Foot Locker on September 8, 2025, for ~$2.5B total consideration: ~$200M cash + 9.6M DICK'S shares. On September 11, DICK'S issued $381.9M of 4.0% Senior Notes due 2029 in exchange for Foot Locker's debt; $18.1M Foot Locker notes remained unexchanged. Pro forma combined net sales for FY2026: $21.78B; combined net income: $564M (vs. standalone DICK'S $849M).

For fiscal year ended June 30, 2026, Marygold reported revenue of $25.3M (up 8% from $23.4M) but net loss of $4.4M ($0.10/share), improved from $5.8M loss ($0.14/share) prior year. The improvement was offset by $3.6M impairment charges: $2.7M intangible asset write-off from UK financial services losses and $0.9M investment impairment. The company is divesting non-core operations: sold Canadian security business, paused U.S. and U.K. fintech, designated New Zealand subsidiaries (Gourmet Foods, Printstock) as discontinued operations for sale. Stockholders' equity fell from $23.0M to $19.2M; cash declined from $5.0M to $2.9M. USCF Investments (fund management) drove growth with 23% revenue increase and 41% AUM growth to $4.1B; Original Sprout returned to profitability with 13% revenue growth.

For fiscal year ended June 30, 2026, Bloomia Holdings reported revenue of $48.1M (down 0.6% YoY) but took a $13.2M non-cash impairment charge ($11.1M goodwill, $2.0M intangibles), resulting in net loss of $11.2M vs. $2.6M prior year. Operationally, the company was hit by 21% bulb cost inflation and 6% Euro appreciation, plus an industry-wide mite infestation that destroyed $2.5M of inventory in Q4. However, management retired $19M of debt obligations via a February-April 2026 rights offering, issuing ~3M shares at $4.05/share for $12.1M gross proceeds ($5M cash, $7.1M debt conversion), reducing total debt 36% to $21.7M from $34.1M and interest expense 33% in Q4.

TechPrecision Corp (guarantor) and borrower entities obtained a 15th amendment to their loan facility with Beacon Bank Trust, extending the revolving line of credit maturity date from an unspecified prior date to October 16, 2026. The amendment acknowledges multiple existing defaults on debt service coverage ratio and leverage covenants spanning 8 quarters (Sept 2023–June 2025); the lender explicitly reserved all rights to accelerate and demand immediate repayment. TechPrecision paid $15,000 (prior failure-to-perform fee) + $2,500 (modification fee) + legal expenses to obtain the extension.

DSS Inc. (market cap ~$2.8M) issued a $500,000 convertible promissory note to Alset Inc. (dated September 15, 2026) convertible at $0.50/share into common stock, plus 8,000,000 warrants exercisable at $0.55/share for 5 years. Conversion of the note requires stockholder approval. The note bears 3% annual interest, matures on demand or in 5 years, and is redeemable by DSS after one year. Alset receives standard piggyback registration rights and anti-dilution protections. The deal represents approximately 18% of DSS's current market capitalization in principal amount alone.

Eric Dube, Ph.D. voluntarily resigned as President and CEO effective December 1, 2026, with employment terminating February 15, 2027. Bradley Campbell was hired as the new President and CEO, effective December 1, 2026, with a base salary of $1,000,000 annually, target bonus of 85% ($850,000), and initial equity grants valued at approximately $16.5 million ($8.25M stock options + $8.25M time-based RSUs), plus a $3.75M performance-based RSU award in early 2027. Dube receives transition assistance payments and consulting engagement through February 15, 2027, with up to 18 months of COBRA premium coverage and equity acceleration provisions if consulting is terminated.

AMC announced a $2B first lien notes offering (due 2031) plus $850M first lien term loan and $1.12B second lien term loan (committed by Deutsche Bank) to refinance existing debt. The company is running a tender offer for $360M of outstanding 7.500% Senior Secured Notes due 2029 at $1,009.70 per $1,000 principal, with settlement expected October 5, 2026. Proceeds will repay existing debt, redeem $903.4M Muvico notes, and fund related costs. The refinancing is conditioned on closing $3.97B aggregate proceeds by settlement date. Two-month results (ended August 31, 2026) show strong operating recovery: consolidated revenue up 42.2% YoY to $1.335B, attendance up 35.9% to 58.2M patrons, revenue per patron up 4.8% to $22.93. Cash on hand: $832.5M.

Executive Officer Pedras Carlos Henrique Villela (BBD) bought 56K shares (~$1.0M) on the open market (25% of holdings). Open-market insider purchase — historically a bullish signal.

AnaptysBio reported Jemperli global net sales of $644M (£480M) for H1 2026, up 34% YoY, generating $53M collaboration revenue. Positive interim AZUR-1 trial data supports February 2027 FDA PDUFA decision for monotherapy in dMMR/MSI-H rectal cancer, with potential expedited review via National Priority Voucher. Separately, Delaware Chancery Court trial (July 2026) against GSK and Tesaro concluded; post-trial hearing scheduled October 20, 2026, with judgment anticipated Q4 2026 or Q1 2027; Anaptys seeks reversion of Jemperli rights.

Executive Officer de Souza Cintia Scovine Barcelos (BBD) bought 60K shares (~$1.1M) on the open market (18% of holdings). Open-market insider purchase — historically a bullish signal.

Executive Officer de Oliveira Andre Luis Duarte (BBD) bought 309K shares (~$5.6M) on the open market (36% of holdings). Open-market insider purchase — historically a bullish signal.

The U.S. Army Corps of Engineers published a Notice of Intent (NOI) on September 21, 2026, formally initiating the Environmental Impact Statement (EIS) process for Trilogy's 50%-owned Arctic copper-zinc-lead-gold-silver project in Alaska (via joint venture Ambler Metals LLC with South32). The milestone launches the NEPA public scoping phase and keeps the project on an accelerated 29-month federal/state permitting schedule targeting a draft EIS in October 2027 and Record of Decision in September 2028.

Paul A. Perrault, CEO and President of Beacon Financial Corp (market cap ~$1.1B) for 17 years, retired effective September 21, 2026. Sean A. Gray, former Chief Operating Officer, was appointed CEO and Board member the same day. Perrault receives: equity vesting per Good Leaver Policy, 2026 bonus, continued medical/dental, and $120,000/month consulting fee for 12 months plus 24 months life/disability insurance; he is subject to 2-year non-compete, confidentiality, and non-solicitation covenants in the geographic footprint where Beacon operates.

Sajal Srivastava, Co-Founder and Co-CEO of TriplePoint Capital, will depart effective December 31, 2026, leaving Jim Labe as sole CEO. Simultaneously, Srivastava steps down as President and CIO of TPVG and sister company TPVC, replaced by Ian Schworer (12-year TriplePoint veteran, former Chief Credit Officer). Schworer assumes CIO role across both entities on the same date; Srivastava remains a director until year-end.

In September 2026, PDS Biotech completed financing led by NantCapital and added Dr. Patrick Soon-Shiong to the Board. The company is refocusing on PDS0301 (tumor-targeted IL-12 immunocytokine), which showed 71.4% objective response rate and ~80% 24-month survival in Phase 2 mCRC with liver metastases (n=22 treated patients). A registrational Phase 3 protocol is in design; five data readouts are expected Q4 2026–Q2 2028 across prostate cancer, colorectal cancer, and Kaposi sarcoma. PDS0101 (HPV vaccine) is being deprioritized and the company is seeking strategic partnership or external funding for it.